pds01adc
Genitourinary Cancer
National Cancer Institute (NCI)Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Genitourinary Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Spanish Oncology Genito-Urinary Group | Phase 2 | B |
Tadalafil Regina Elena Cancer Institute | Phase 3 | B |
Ipilimumab Dana-Farber Cancer Institute | Phase 2 | B |
Atezolizumab British Columbia Cancer Agency | Phase 2 | B |
AMCASERTIB Sumitomo Pharma America, Inc. | Phase 2 | CCC |
View all 31 →
Same molecule, other indications
pds01adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →